IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq: LBIO) concerning possible violations of federal securities laws.
If you purchased shares of Lion and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation focuses on whether Lion and certain of its officers and/or directors violated federal securities laws. On April 10, 2017, the Securities & Exchange Commission found that between September 2013 and March 2014, the Company’s former CEO, Manish Singh, misled investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when they were actually paid promotions.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.